PET for Drug Development and Evaluation

Part one: Introduction. 1. Drug development and positron emission tomography; B. Campbell. 2. Positron emission tomography: Basic principles and potential interest for pharmacological studies; B. Mazoyer. 3. Is PET a tool for drug evaluation? B. Långström, et al. Part two: Psychiatry. 4. PET in neuropsychiatric drug development; L. Farde. 5. Radioligand disposition and metabolism - Key information in early drug development; C. Halldin, et al. 6. PET studies in the early clinical development of a new antipsychotic; J.M. Sitsen, L. Farde. 7. PET in the development of Dopamine D1 antagonists as new potential antipsychotic drugs; C. Foged, et al. 8. Is the 5-HT2-receptor a target for antipsychotic drug action? PET studies on dopamine (D2) and serotonin (5-HT2) receptor occupancy in patients and healthy subjects; S. Nyberg, et al. 9. Preclinical development of a radioligand for the study of central 5-HT1a receptors with PET-[11C]WAY-100635; V.W. Pike, et al. 10. Comparative in vivo and vitro selectivity of zolpidem for omega (Benzodiazepine) modulatory site subtypes; J. Benavides, et al. 11. Do the effects of muscarinic receptor blockade on brain glucose consumption mimic the cortical and subcortical metabolic pattern of Alzheimer's disease in normal volunteers? J. Blin, et al. Part three: Neurology. 12. PET evaluation of drug treatment in ischemic stroke and Alzheimer's disease; W.- D. Heiss. 13. PET imaging of cerebral perfusion and oxygen metabolism in acute ischemic stroke: Implications for management and therapy;J.C. Baron. 14. Pharmacokinetics: Kinetic modelling of MAO inhibitors and D2 antagonists; A. Lammertsma, C.J. Bench. 15. Brain activation under drug treatment; P. Grasby, K.J. Friston. 16. Modifying the progression of Parkinson's disease; P. Morrish, et al. 17. COMT inhibition: Pharmacology of tolcapone and 6- (18F)-Fluoro-L-Dopa (FDOPA) PET results; K. Jorga. 18. Interaction of Lisuride with dopaminergic receptors; B. Mazière, A. Antonini. 19. Lisuride